Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Cyclosporine to Tacrolimus in Kidney Transplant Recipients
NCT02268201Phase 4Terminated
- Sponsor
- Astellas Pharma
- Start
- Jul 2013
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus + Wuzhi capsule in kidney transplant rejection (2 arms), sponsored by Astellas Pharma. Primary endpoint: Medication Adherence at 52 weeks. Started Jul 2013; status: terminated.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02268201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268201.